FDX1 and adrenal cortex carcinoma: The expression of FDX1 was not significantly different in most cancers by clinical stage, age, and gender, but in some cancers, especially ACC, KIRC, HNSC, MESO, and THCA, it could serve as an independent prognostic factor and a potential prognostic marker.